PE44997A1 - Formulacion oral de 2-metil-tieno-benzodiacepina (olanzapina) y procedimiento de preparacion - Google Patents

Formulacion oral de 2-metil-tieno-benzodiacepina (olanzapina) y procedimiento de preparacion

Info

Publication number
PE44997A1
PE44997A1 PE1996000204A PE00020496A PE44997A1 PE 44997 A1 PE44997 A1 PE 44997A1 PE 1996000204 A PE1996000204 A PE 1996000204A PE 00020496 A PE00020496 A PE 00020496A PE 44997 A1 PE44997 A1 PE 44997A1
Authority
PE
Peru
Prior art keywords
olanzapine
oral formulation
hydroxypropilcellulose
refers
benzodiacepine
Prior art date
Application number
PE1996000204A
Other languages
English (en)
Inventor
Clifford Morris Tommy
Randall Cochran George
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23624847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE44997(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE44997A1 publication Critical patent/PE44997A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A UNA COMPOSICION ANTIPSICOTICA, DONDE: EL PRINCIPIO ACTIVO ES LA FORMA POLIMORFICA ALTAMENTE PURA DE OLANZAPINA DE 1% A 3% P/P, CARACTERIZADO POR VALORES DE ESPACIOS INTERPLANARES DE 10,2689A� A 2,6007A� APROXIMADAMENTE; EL AGENTE DE CARGA ES LACTOSA DE 69,5% A 87,5% P/P, EL AGLUTINANTE ES HIDROXIPROPILCELULOSA DE 3,5 A 4,5% P/P, EL DISGREGANTE ES CROSPOVIDONA DE 4% A 6% P/P, EL AGLUTINANTE SECO ES CELULOSA MICROCRISTALINA DE 9% A 11%; EL LUBRICANTE ES ESTEARATO DE MAGNESIO DE 0,25% A 1%; EN LA RECUBIERTA AL POLIMERO SELECCIONADO ENTRE HIPROMELOSA, HIDROXIPROPILCELULOSA Y ETILCELULOSA, ENTRE OTROS, MAS PREFERIBLEMENTE HIDROXIPROPILHIPROMELOSA; EN EL SOBRECUBRIMIENTO AL HIDROXIPROPILHIPROMELOSA RECUBIERTO ADICIONALMENTE CON UNA PELICULA EN DISPERSION ACUOSA. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DE UNA FORMULACION ORAL SOLIDA, QUE COMPRENDE LA GRANULACION HUMEDA ACUOSA DE ALTA CIZALLA Y EL SECADO EN LECHO FLUIDO. ESTA FORMULACION NO PERMITE EL CAMBIO DE COLOR FARMACEUTICAMENTE NO ACEPTABLE, BAJO CONDICIONES DE ALMACENAMIENTO
PE1996000204A 1995-03-24 1996-03-22 Formulacion oral de 2-metil-tieno-benzodiacepina (olanzapina) y procedimiento de preparacion PE44997A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41046595A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
PE44997A1 true PE44997A1 (es) 1997-10-23

Family

ID=23624847

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000204A PE44997A1 (es) 1995-03-24 1996-03-22 Formulacion oral de 2-metil-tieno-benzodiacepina (olanzapina) y procedimiento de preparacion

Country Status (46)

Country Link
US (4) US5919485A (es)
EP (2) EP1093815B1 (es)
JP (1) JPH11502848A (es)
KR (1) KR100408172B1 (es)
CN (1) CN1178662C (es)
AP (1) AP679A (es)
AR (2) AR001405A1 (es)
AT (3) AT405606B (es)
AU (1) AU696601B2 (es)
BG (1) BG62594B1 (es)
BR (1) BR9607791A (es)
CA (1) CA2216372C (es)
CH (1) CH691217A5 (es)
CO (1) CO4700474A1 (es)
CR (1) CR5278A (es)
CZ (1) CZ296007B6 (es)
DE (3) DE69634053T2 (es)
DK (3) DK0733367T3 (es)
EA (1) EA000938B1 (es)
EE (1) EE03551B1 (es)
EG (1) EG24077A (es)
ES (2) ES2164837T3 (es)
FI (1) FI973749L (es)
GB (1) GB2313783B (es)
HU (1) HU225269B1 (es)
IL (1) IL117611A (es)
IS (1) IS1903B (es)
LT (1) LT4350B (es)
LU (1) LU90115B1 (es)
LV (1) LV11983B (es)
MY (1) MY113440A (es)
NO (1) NO320388B1 (es)
NZ (1) NZ306111A (es)
OA (1) OA10511A (es)
PE (1) PE44997A1 (es)
PL (1) PL188316B1 (es)
PT (2) PT733367E (es)
RO (1) RO118370B1 (es)
SE (1) SE9703206D0 (es)
SI (3) SI0733367T1 (es)
SK (1) SK283745B6 (es)
TR (1) TR199701018T1 (es)
TW (1) TW426526B (es)
UA (1) UA44766C2 (es)
WO (1) WO1996029995A1 (es)
ZA (1) ZA962338B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
CA2266448A1 (en) * 1996-09-24 1998-04-02 Eli Lilly And Company Coated particle formulation
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
WO2001047933A1 (en) * 1999-12-28 2001-07-05 Cipla Limited New polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
US20030072729A1 (en) * 2001-05-15 2003-04-17 Christopher Szymczak Simethicone as weight gain enhancer
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2003086361A1 (en) * 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
SI1513846T1 (sl) 2002-05-31 2011-11-30 Sandoz Ag Postopek za pripravo olanzapina form I
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US7029112B2 (en) 2002-08-05 2006-04-18 Mars, Incorporated Ink-jet printing on surface modified edibles and products made
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
EP1670441A4 (en) * 2003-10-07 2012-05-02 Andrx Pharmaceuticals Llc FAST RESOLUTION FORMULATION
EP1684734A2 (en) * 2003-11-18 2006-08-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) * 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
EP1838716B1 (en) 2005-01-05 2011-06-01 Eli Lilly And Company Olanzapine pamoate dihydrate
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP2008536922A (ja) * 2005-04-22 2008-09-11 テバ・ファーマシューティカルズ・ユーエスエー・インコーポレイテッド オランザピンの医薬用経口崩壊錠
PL1885383T3 (pl) * 2005-05-31 2017-06-30 Iams Europe B.V. Kocie probiotyczne bifidobakterie
BRPI0611493B1 (pt) * 2005-05-31 2022-04-05 Alimentary Health Ltd. Lactobacilos probióticos felinos
US20070014847A1 (en) * 2005-07-05 2007-01-18 Ahmed Salah U Coated capsules and methods of making and using the same
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
DE602006014030D1 (de) * 2006-07-05 2010-06-10 Bilim Ilac Sanayii Ve Ticaret Stabile olanzapin-formulierung mit antioxidantien
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
EP2124966B1 (en) 2007-02-01 2015-09-09 IAMS Europe B.V. Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
CA2713677A1 (en) * 2008-01-31 2009-08-06 Kyorin Pharmaceutical Co., Ltd. Method for production of orally rapidly disintegrating tablet comprising imidafenacin as active ingredient
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
GB2472965A (en) * 2009-03-25 2011-02-23 Caitin Inc Supersonic cooling system
US8505322B2 (en) * 2009-03-25 2013-08-13 Pax Scientific, Inc. Battery cooling
US20110048048A1 (en) * 2009-03-25 2011-03-03 Thomas Gielda Personal Cooling System
US20110051549A1 (en) * 2009-07-25 2011-03-03 Kristian Debus Nucleation Ring for a Central Insert
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8365540B2 (en) * 2009-09-04 2013-02-05 Pax Scientific, Inc. System and method for heat transfer
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9517212B1 (en) * 2012-11-15 2016-12-13 Chandra Zaveri Medicated adhesive pad arrangement
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法
WO2015036512A1 (en) * 2013-09-13 2015-03-19 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
BR112019024987A2 (pt) * 2017-06-02 2020-06-16 Xeris Pharmaceuticals, Inc. Formulações de fármaco de molécula pequena resistente à precipitação
CN113143878A (zh) * 2021-03-19 2021-07-23 杭州新诺华医药有限公司 奥氮平组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US4172831A (en) * 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
ZA922776B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical compounds
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
AU668159B2 (en) * 1992-05-29 1996-04-26 Lilly Industries Limited Pharmaceutical compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
BR9607791A (pt) 1998-07-07
FI973749A0 (fi) 1997-09-22
ATA902296A (de) 1999-02-15
US20010018071A1 (en) 2001-08-30
US5919485A (en) 1999-07-06
NO320388B1 (no) 2005-11-28
WO1996029995A1 (en) 1996-10-03
TW426526B (en) 2001-03-21
SI0733367T1 (en) 2002-06-30
PT1093815E (pt) 2005-03-31
FI973749A7 (fi) 1997-09-22
CR5278A (es) 1996-07-04
CA2216372C (en) 2007-11-20
DE69615887T2 (de) 2002-04-11
AU696601B2 (en) 1998-09-17
CZ296007B6 (cs) 2005-12-14
CA2216372A1 (en) 1996-10-03
ES2164837T3 (es) 2002-03-01
US7229643B2 (en) 2007-06-12
HU225269B1 (en) 2006-08-28
CN1178662C (zh) 2004-12-08
PL188316B1 (pl) 2005-01-31
AR002720A1 (es) 1998-04-29
IL117611A0 (en) 1996-07-23
DK1093815T3 (da) 2005-04-25
EA199700260A1 (ru) 1998-02-26
DE69634053D1 (de) 2005-01-20
EE9700328A (et) 1998-06-15
SI9620041A (sl) 1998-06-30
CH691217A5 (de) 2001-05-31
EA000938B1 (ru) 2000-06-26
MX9707186A (es) 1997-11-29
EP1093815A1 (en) 2001-04-25
ZA962338B (en) 1997-09-22
NZ306111A (en) 1999-02-25
DE19681287T1 (de) 1998-03-19
ATE206924T1 (de) 2001-11-15
DK0733367T3 (da) 2001-11-26
GB2313783B (en) 1998-11-18
CZ300197A3 (en) 1997-12-17
LT4350B (lt) 1998-05-25
HUP9800410A2 (hu) 1998-07-28
EG24077A (en) 2008-05-11
PL322579A1 (en) 1998-02-02
SK128297A3 (en) 1998-03-04
US20050085462A1 (en) 2005-04-21
AP679A (en) 1998-09-28
EE03551B1 (et) 2001-12-17
US6780433B2 (en) 2004-08-24
MY113440A (en) 2002-02-28
DK109097A (da) 1997-11-12
FI973749L (fi) 1997-09-22
EP0733367B1 (en) 2001-10-17
AP9701064A0 (en) 1997-10-31
NO974363D0 (no) 1997-09-22
CO4700474A1 (es) 1998-12-29
SE9703206L (sv) 1997-09-05
ATE284695T1 (de) 2005-01-15
EP0733367A1 (en) 1996-09-25
EP1093815B1 (en) 2004-12-15
DK173323B1 (da) 2000-07-24
LT97149A (lt) 1998-01-26
OA10511A (en) 2002-04-24
AU5428096A (en) 1996-10-16
SE9703206D0 (sv) 1997-09-05
GB2313783A (en) 1997-12-10
CN1179102A (zh) 1998-04-15
US6190698B1 (en) 2001-02-20
BG62594B1 (bg) 2000-03-31
DE69634053T2 (de) 2005-12-22
IS1903B (is) 2003-11-20
TR199701018T1 (xx) 1998-01-21
DE69615887D1 (de) 2001-11-22
IS4565A (is) 1997-09-22
HUP9800410A3 (en) 2000-01-28
KR100408172B1 (ko) 2004-02-18
SK283745B6 (sk) 2003-12-02
IL117611A (en) 2002-05-23
KR19980703189A (ko) 1998-10-15
RO118370B1 (ro) 2003-05-30
AR001405A1 (es) 1997-10-22
LV11983B (en) 1998-07-20
JPH11502848A (ja) 1999-03-09
LV11983A (lv) 1998-03-20
SI1093815T1 (en) 2005-06-30
NO974363L (no) 1997-11-17
PT733367E (pt) 2002-03-28
UA44766C2 (uk) 2002-03-15
GB9719817D0 (en) 1997-11-19
ES2232379T3 (es) 2005-06-01
AT405606B (de) 1999-10-25
BG101901A (bg) 1998-10-30
LU90115B1 (fr) 1997-09-10

Similar Documents

Publication Publication Date Title
GR880100258A (en) Preparation method of a mould for the retarded liberating of impuprofene
US5601845A (en) Pharmaceutical spheroid formulation
CR5278A (es) Formulacion oral de 2-metil-tieno-benzodiacepina
ES2083074T3 (es) Dispositivo de liberacion controlada.
ES2042561T3 (es) Un proceso para la preparacion de una composicion farmaceutica solida de liberacion controlada para administracion oral, rectal o vaginal.
EP1859790A3 (en) Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
BR9912300A (pt) Composição farmacêutica oral de um composto tendo atividade antifúngica e método para a sua preparação
DE58901990D1 (de) Feste pharmazeutische retardform.
KR20010062478A (ko) 경구투여후 트리메트아지딘의 지속적 방출을 가능케 하는매트릭스 정제
KR920019340A (ko) 최적화된 정제 제제
BR0114196A (pt) Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.
PE27899A1 (es) Formulacion de particulas revestidas
ES2175073T3 (es) Procedimiento de preparacion de formas para la administracion oral de antibioticos beta-lactamicos de rapida dispersabilidad en agua.
ES509798A0 (es) Procedimiento para la obtencion de lapices antimicoticos con mayor liberacion de sustancia activa.
AR017222A1 (es) Procedimiento de utilizacion de un agente que inhibe el desarrollo de p.ovale, en la preparacion de medicamentos
CA2466726C (en) Preparation composition containing acid-unstable physiologically active compound and process for producing same
ES546799A0 (es) Procedimiento para la obtencion de formulaciones medicionales solidas de nitrendipina cristalina.
CA2001673A1 (en) Pharmaceutical composition containing piroxicam
ES2090490T3 (es) Supositorios de liberacion prolongada y un procedimiento para su preparacion.
JP2002518334A5 (es)
RU2004122479A (ru) Содержащая свехчистую флудару пероральная композиция с быстрым высвобождением действующего вещества
DE3877621D1 (de) Trockene orale theophyllinzubereitung mit verzoegerter freisetzung.
WAN et al. Liquid penetration into tablets containing surfactants
CO4970814A1 (es) Formulaciones de tiagabine de liberacion prolongada con efec tos secundarios reducidos
TH25938A (th) สูตรผสมของ 2-เมธิล-ไธเอโน-เบนโซไดแอซิฟีน สำหรับ?ใช้ทางปาก

Legal Events

Date Code Title Description
FG Grant, registration
MC Annulment